Biometric Underwriting Data Quality: What Reinsurers Audit First

Biometric underwriting data quality is the first thing reinsurers examine when they evaluate an accelerated underwriting program, and it's where most programs stumble before they ever get to mortality analysis. The data itself—how it's captured, stored, validated, and tracked over time—determines whether a reinsurer will price your treaty competitively or walk away from the table.

This is a shift from how reinsurance audits worked a decade ago. Traditional programs submitted labs and paramedical results with well-understood error profiles. The data formats were standardized. The failure modes were known. Biometric data from smartphones, cameras, and wearable sensors introduces an entirely different set of questions that most reinsurers are still figuring out how to ask.

The SOA's 2022 Accelerated Underwriting Practices Survey found that the percentage of new life business assumed by reinsurers under accelerated underwriting programs jumped from 6% in 2019 to 35% by 2022. As that share grows, so does the scrutiny on the data feeding those decisions.

What reinsurers actually audit in biometric underwriting data

The audit process has changed as biometric data sources have moved from supplemental curiosities to core decision inputs. Reinsurers aren't just checking whether the data exists. They're testing whether the data is reliable enough to underwrite against.

Device and capture environment consistency

The first audit question is deceptively simple: what device captured the data, and under what conditions? A blood pressure reading from a clinical-grade cuff in a controlled environment is a very different animal from an rPPG-derived estimate captured on a three-year-old Android phone in a dimly lit room.

Munich Re's 2024 Accelerated Underwriting Survey found that carriers using digital health data sources varied widely in how they documented capture conditions. Some tracked device model, OS version, lighting conditions, and session duration. Others recorded essentially nothing beyond the final output number. Reinsurers reviewing those programs drew very different conclusions about data trustworthiness.

The audit typically checks for:

• Device metadata logging (make, model, OS, camera specs)
• Environmental condition tracking (lighting, motion, background noise)
• Session quality scores that gate whether a reading is accepted or rejected
• Retry and retest protocols when quality thresholds aren't met

Signal quality and rejection rates

Raw rejection rates tell reinsurers more about a program's integrity than almost any other single metric. If a biometric screening tool accepts 99.5% of all attempts, either it's working in perfectly controlled conditions every time (unlikely at scale) or it's passing through low-quality signals that shouldn't be used for underwriting decisions.

The NAIC's June 2024 draft regulatory guidance on accelerated underwriting specifically called out the need for insurers to "take steps to ensure data inputs are transparent, accurate, reliable, and the data is being used in a manner consistent with sound actuarial practices." That language was aimed squarely at newer digital data sources where quality standards haven't calcified yet.

A reinsurer reviewing signal quality typically wants to see:

• What percentage of capture attempts are rejected for quality reasons
• Whether rejection thresholds have changed over time (and why)
• How borderline readings are handled—rounded, retested, or flagged
• Whether there's a correlation between rejection rates and applicant demographics

Data completeness and missing value handling

Missing data is a fact of life in any underwriting program. The question is what happens when a biometric reading comes back incomplete. Did the system impute a value? Did it escalate to manual review? Did it substitute data from a different source?

The SOA's 2019 Accelerated Underwriting Practices Survey, conducted by Milliman, reported that reinsurers consistently flagged missing value handling as a top concern. One reinsurer noted that data quality from direct companies was "average" but "improving quickly," suggesting the bar was low to begin with. The tips reinsurers offered for running a successful program centered on transparency about data gaps rather than pretending they didn't exist.

Longitudinal consistency

One reading means almost nothing in isolation. Reinsurers want to see how biometric data behaves over repeated captures—both within a single applicant's session and across the applicant population. If heart rate readings from the same person vary by 25 BPM between two captures taken five minutes apart, the measurement system has a precision problem that no amount of statistical modeling can paper over.

Gen Re's 2024 U.S. Individual Life Accelerated Underwriting Survey highlighted throughput rates and data source usage as key areas where carrier practices diverged significantly. The carriers with higher reinsurer confidence scores were the ones that could demonstrate measurement repeatability with statistical rigor.

Biometric data quality audit comparison

Reinsurers don't evaluate all data quality dimensions equally. Some are table stakes. Others differentiate programs.

Audit dimension	What reinsurers check	Priority level	Common failure mode
Device metadata logging	Capture device, OS, sensor specs recorded per session	High	No metadata captured; only final value stored
Signal quality gating	Rejection thresholds, quality scores, acceptance criteria	Critical	Thresholds set too permissively; low-quality reads accepted
Missing value protocols	How gaps are handled—imputation, escalation, substitution	High	Silent imputation without documentation
Capture environment	Lighting, motion, noise, session duration tracked	Medium	Environment not recorded; assumed adequate
Repeatability evidence	Test-retest consistency data across captures	Critical	No repeatability studies conducted
Demographic bias testing	Performance across age, skin tone, device type	High	Testing limited to narrow population slice
Data lineage and versioning	Algorithm version, model updates, data pipeline changes tracked	Medium	No version tracking; impossible to audit retrospectively
Consent and governance	Applicant consent records, data retention policies, access logs	High	Consent language doesn't cover reinsurer access

Programs that check the "critical" boxes with solid documentation get through reinsurer due diligence faster. The ones that treat data quality as an afterthought end up in prolonged negotiations or face unfavorable treaty terms.

How data quality failures show up in treaty pricing

The financial impact of poor biometric data quality isn't abstract. It shows up directly in how reinsurers price the treaty.

Risk margins and uncertainty loading

When a reinsurer can't verify the quality of the data underlying an accelerated program, they add uncertainty margins. These aren't small adjustments. PartnerRe's guidance on setting best estimate assumptions for biometric risk emphasizes that valuations should be based on data meeting three criteria: accuracy, completeness, and appropriateness. Data that fails any of those tests triggers wider confidence intervals and higher margins.

In practice, this means a carrier with a well-documented biometric data pipeline might get treaty pricing with mortality margins of 5-10% above best estimate. A carrier with sparse documentation and no repeatability data might face margins of 20-30% or more. The difference compounds over thousands of policies.

Experience study limitations

Reinsurers conduct experience studies to compare actual mortality against expected mortality for accelerated programs. But these studies are only as good as the data they're built on. If biometric readings can't be traced back to specific algorithm versions, device types, and quality scores, the experience study results become difficult to interpret.

Did mortality worsen because the risk selection was poor, or because algorithm version 3.2 had a calibration drift that went undetected for six months? Without proper data lineage, no one can answer that question. And when no one can answer it, the reinsurer prices the uncertainty.

What carriers get wrong about biometric data governance

Treating the biometric reading as the final product

The most common mistake is storing only the output—a heart rate number, a blood pressure estimate, a stress score—without preserving the context that produced it. Reinsurers reviewing these programs have no way to assess whether the number is trustworthy. It's like receiving a lab result without knowing which lab ran it, what equipment they used, or whether the sample was handled properly.

Good programs store the full context: device metadata, environmental conditions, quality scores, algorithm version, session duration, number of retry attempts, and the confidence interval around the output. That context is what reinsurers actually audit.

Assuming current validation data covers future performance

A validation study conducted on 500 people using iPhone 14s in a clinical setting does not tell you much about how the system performs on 50,000 applicants using whatever phone they happen to own, in whatever room they happen to be sitting in. Reinsurers have learned this lesson and now ask specifically about real-world performance data, not just controlled validation results.

Munich Re's biometric analytics team has built tools specifically for benchmarking and actuarial analyses of biometric data in production environments, signaling that the industry is moving past the "trust the validation study" phase.

Ignoring algorithm versioning

Biometric algorithms get updated. Models are retrained. Calibration parameters shift. If a carrier can't tell a reinsurer which algorithm version produced which underwriting decisions, the entire dataset becomes suspect during retrospective analysis. This is basic data governance, but it's surprisingly rare in practice.

Industry use cases and where biometric data quality matters most

Accelerated underwriting at scale

The carriers pushing past 50% acceleration rates are the ones investing heavily in data quality infrastructure. When you're algorithmically deciding half your book without human review, the data quality of every input becomes a direct driver of mortality outcomes. There's no underwriter catching the bad readings at the back end.

Fluidless programs for younger demographics

Programs targeting applicants under 40 with face amounts under $500,000 are prime territory for biometric-only underwriting. But this demographic also shows the widest device diversity—older phones, inconsistent lighting, more rushed capture sessions. Data quality controls matter more here precisely because the population introduces more variability. (We explored the broader architecture of fluidless programs in our 2026 analysis.)

Group and voluntary benefits

Group programs running biometric screening across thousands of employees in a benefits enrollment window face unique data quality challenges. The captures happen in bulk, often in suboptimal conditions, and there's less individual attention to session quality. Reinsurers pricing group treaties with biometric components have started requiring separate data quality reports for the group capture environment.

Current research and evidence

The SOA has published multiple rounds of accelerated underwriting surveys through Milliman, with the 2019 and 2022 reports providing the most detailed reinsurer perspectives on data quality expectations. Al Klein's analysis in the SOA Reinsurance Section newsletter (February 2024) noted that reinsurer participation in accelerated underwriting programs increased substantially between 2019 and 2022, with data quality emerging as the primary differentiator between programs that attracted competitive terms and those that didn't.

Munich Re's 2024 Accelerated Underwriting Survey, combined with MIB analysis, documented how electronic health record adoption is changing the data quality baseline that reinsurers expect. The report found that content quality of EHR data varied significantly by source, and that carriers combining EHR data with biometric inputs needed separate quality frameworks for each data stream.

The NAIC's Accelerated Underwriting Working Group released draft regulatory guidance in June 2024 that explicitly addressed data quality standards for digital underwriting inputs, calling for transparency, accuracy, and reliability as baseline requirements.

The future of biometric data quality in reinsurance

The audit process is getting more sophisticated, not less. Reinsurers are building internal teams specifically to evaluate digital health data pipelines—something that didn't exist five years ago. The carriers who invest in data quality infrastructure now are building a durable competitive advantage in treaty negotiations.

Contactless measurement technologies, including camera-based rPPG systems, are adding new biometric signals to the underwriting toolkit. Companies like Circadify are developing smartphone-based vital signs capture that generates the kind of structured, metadata-rich output that reinsurers need for proper audit trails. The gap between "we collect biometric data" and "we collect auditable biometric data" is where the next round of competitive differentiation will happen.

As reinsurer expectations formalize into explicit standards—something the NAIC's working group and the SOA's ongoing research are actively pushing toward—carriers without strong data quality foundations will find themselves locked out of competitive treaty terms. The time to build that infrastructure was two years ago. The second-best time is now.

Frequently asked questions

What is the first thing reinsurers look at in a biometric underwriting audit?

Signal quality gating and rejection rates. Reinsurers want to know what percentage of biometric capture attempts are rejected for quality reasons and whether those thresholds are appropriately calibrated. A program that accepts nearly everything raises immediate red flags about data integrity.

How does poor biometric data quality affect treaty pricing?

Reinsurers add uncertainty margins when data quality can't be verified. Carriers with well-documented biometric data pipelines may see mortality margins of 5-10% above best estimate, while poorly documented programs can face margins of 20-30% or higher. Over a large book, that pricing difference is substantial.

Do reinsurers require specific device or sensor standards for biometric data?

There's no industry-wide device standard yet, but reinsurers expect carriers to log device metadata (make, model, OS, camera specs) for every capture session. The audit focuses on whether the carrier can demonstrate consistent performance across the range of devices their applicants actually use.

How often should carriers update their biometric data quality documentation for reinsurers?

At minimum, every time the underlying algorithm or capture process changes. Best practice is quarterly reporting that covers rejection rates, repeatability metrics, device distribution, and any algorithm version updates. Reinsurers conducting experience studies need this data to properly attribute mortality outcomes.